INTRODUCTIONEwing sarcoma is the second most common primary bone neoplasm in childhood and adolescence. Tumors located in the pelvis and spine account for approximately 25% and 8% of all primary sites, respectively. Studies have reported that multiple pre‐treatment and post‐treatment prognostic factors exist including age, gender, tumor size, primary site, metastatic status, and response to chemotherapy. Clinical outcomes among different risk groups vary significantly, with the 5‐year event‐free survival rate for localized non‐pelvic tumors reaching 60% while that of pelvic or sacral tumors remaining as low as 30‐50%.Treatment of Ewing sarcoma involves multi‐agent systemic chemotherapy as well as local therapy consisting of either surgery, radiation or both. Although there have been abundant randomized clinical trials comparing chemotherapy regimens, prospective studies have not assessed the impact of local control choices on clinical endpoints. Local control for Ewing sarcoma of the spine and pelvis is especially challenging as wide resection may not be feasible in some circumstances either due to the risk of iatrogenic neurologic compromise or due to reconstructive challenges inherent in large pelvic defects. Marginal or intra‐lesional resections have been associated with inferior outcomes and current recommendations advise against this approach for local control. While Ewing sarcoma is considered
Journal of Surgical Oncology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera